Compare Crispr Therapeutics AG (CRSP) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Workday Inc — how do they compare? Crispr Therapeutics AG trades at $53.76 (market cap $5.23B), while Workday Inc trades at $173.81 (market cap $44.77B). The key difference: Workday Inc is far larger — about 8.6× Crispr Therapeutics AG's market cap, and Workday Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | WDAY | |
|---|---|---|
Market Cap | $5.23B | $44.77B |
Sector | Health | Technology |
52-Week High | $76.78 | $247.69 |
52-Week Low | $44.34 | $112.55 |
Enterprise Value | $3.65B | $44.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Workday (WDAY) trades at $174.5, down 5.26% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong revenue growth, reaching $8.45B in 2025, with consistent earnings beats and a high gross margin of 75.77%. Recent news highlights product launches like Workday Adaptive Planning's FedRAMP authorization and an AI-native learning platform, reinforcing its enterprise software leadership.
Outlook remains positive with robust fundamentals and analyst support, though elevated valuation ratios like a P/E of 56.47 pose risks. Key opportunities include AI-driven growth in HR and finance software, while risks involve competitive pressures and market volatility. The consensus price target of $153.33 suggests caution near current levels, but long-term growth prospects are solid.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
